186 related articles for article (PubMed ID: 36652977)
1. The effectiveness of tocilizumab and its comparison with tumor necrosis factor alpha inhibitors for Takayasu Arteritis: A systematic review and meta-analysis.
Misra DP; Singh K; Rathore U; Patro P; Tomelleri A; Campochiaro C; Agarwal V; Sharma A
Autoimmun Rev; 2023 Mar; 22(3):103275. PubMed ID: 36652977
[TBL] [Abstract][Full Text] [Related]
2. Disease-modifying anti-rheumatic drugs for the management of Takayasu arteritis-a systematic review and meta-analysis.
Misra DP; Rathore U; Patro P; Agarwal V; Sharma A
Clin Rheumatol; 2021 Nov; 40(11):4391-4416. PubMed ID: 33932173
[TBL] [Abstract][Full Text] [Related]
3. Presentation and clinical course of pediatric-onset versus adult-onset Takayasu arteritis-a systematic review and meta-analysis.
Misra DP; Rathore U; Kopp CR; Patro P; Agarwal V; Sharma A
Clin Rheumatol; 2022 Dec; 41(12):3601-3613. PubMed ID: 35927524
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of tocilizumab in treatment of Takayasu arteritis: A systematic review of randomized controlled trials.
Singh A; Danda D; Hussain S; Najmi AK; Mathew A; Goel R; Lakhan SE; Tajudheen B; Antony B
Mod Rheumatol; 2021 Jan; 31(1):197-204. PubMed ID: 32000551
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab for giant cell arteritis.
Antonio AA; Santos RN; Abariga SA
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD013484. PubMed ID: 34420204
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).
Nakaoka Y; Isobe M; Takei S; Tanaka Y; Ishii T; Yokota S; Nomura A; Yoshida S; Nishimoto N
Ann Rheum Dis; 2018 Mar; 77(3):348-354. PubMed ID: 29191819
[TBL] [Abstract][Full Text] [Related]
7. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
8. Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: A systematic review and meta-analysis.
Barra L; Yang G; Pagnoux C;
Autoimmun Rev; 2018 Jul; 17(7):683-693. PubMed ID: 29729444
[TBL] [Abstract][Full Text] [Related]
9. Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study.
Mekinian A; Biard L; Lorenzo D; Novikov PI; Salvarani C; Espitia O; Sciascia S; Michaud M; Lambert M; Hernández-Rodríguez J; Schleinitz N; Awisat A; Puechal X; Aouba A; Munoz Pons H; Smitienko I; Gaultier JB; Edwige LM; Benhamou Y; Perlat A; Jego P; Goulenok T; Sacre K; Lioger B; Hassold N; Broner J; Dufrost V; Sené T; Seguier J; Maurier F; Berthier S; Belot A; Frikha F; Denis G; Audemard-Verger A; Koné-Paut I; Humbert S; Woaye-Hune P; Tomelleri A; Baldissera EM; Kuwana M; Lo Gullo A; Mukuchyan V; Dellal A; Gaches F; Zeminsky P; Galli E; Alvarado M; Boiardi L; Muratore F; Vautier M; Campochiaro C; Moiseev S; Vieira M; Cacoub P; Fain O; Saadoun D;
RMD Open; 2023 Jun; 9(2):. PubMed ID: 37321669
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Biological-Targeted Treatments in Takayasu Arteritis: Multicenter, Retrospective Study of 49 Patients.
Mekinian A; Comarmond C; Resche-Rigon M; Mirault T; Kahn JE; Lambert M; Sibilia J; Néel A; Cohen P; Hie M; Berthier S; Marie I; Lavigne C; Anne Vandenhende M; Muller G; Amoura Z; Devilliers H; Abad S; Hamidou M; Guillevin L; Dhote R; Godeau B; Messas E; Cacoub P; Fain O; Saadoun D;
Circulation; 2015 Nov; 132(18):1693-700. PubMed ID: 26354797
[TBL] [Abstract][Full Text] [Related]
11. Corticosteroid monotherapy for the management of Takayasu arteritis-a systematic review and meta-analysis.
Misra DP; Rathore U; Patro P; Agarwal V; Sharma A
Rheumatol Int; 2021 Oct; 41(10):1729-1742. PubMed ID: 34302232
[TBL] [Abstract][Full Text] [Related]
12. Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis.
Kang L; Liu Y; Luo Z; Zhou Y; Chen B; Yin G; Xie Q
Front Immunol; 2023; 14():1084558. PubMed ID: 36845158
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of biological agents in the treatment of patients with Takayasu arteritis: a systematic review and meta-analysis.
Shuai ZQ; Zhang CX; Shuai ZW; Ge SL
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):250-262. PubMed ID: 33506914
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients.
Mekinian A; Biard L; Dagna L; Novikov P; Salvarani C; Espitia O; Sciascia S; Michaud M; Lambert M; Hernández-Rodríguez J; Schleinitz N; Awisat A; Puéchal X; Aouba A; Munoz Pons H; Smitienko I; Gaultier JB; Le Mouel E; Benhamou Y; Perlat A; Jego P; Goulenok T; Sacre K; Lioger B; Hassold N; Broner J; Dufrost V; Sene T; Seguier J; Maurier F; Berthier S; Belot A; Frikha F; Denis G; Audemard-Verger A; Kone Pault I; Humbert S; Woaye-Hune P; Tomelleri A; Baldissera E; Kuwana M; Lo Gullo A; Gaches F; Zeminsky P; Galli E; Alvarado M; Boiardi L; Muratore F; Vautier M; Campochiaro C; Moiseev S; Cacoub P; Fain O; Saadoun D;
Rheumatology (Oxford); 2022 Apr; 61(4):1376-1384. PubMed ID: 34363461
[TBL] [Abstract][Full Text] [Related]
15. TNF inhibitors appear to inhibit disease progression and improve outcome in Takayasu arteritis; an observational, population-based time trend study.
Gudbrandsson B; Molberg Ø; Palm Ø
Arthritis Res Ther; 2017 May; 19(1):99. PubMed ID: 28521841
[TBL] [Abstract][Full Text] [Related]
16. Refractory Takayasu arteritis successfully treated with rituximab: case-based review.
Mutoh T; Ishii T; Shirai T; Akita K; Kamogawa Y; Fujita Y; Sato H; Shirota Y; Fujii H; Harigae H
Rheumatol Int; 2019 Nov; 39(11):1989-1994. PubMed ID: 31388749
[TBL] [Abstract][Full Text] [Related]
17. Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap?
Campochiaro C; Tomelleri A; Galli E; Cocchiara E; Sartorelli S; Muratore F; Malattia C; Caorsi R; Catanoso MG; Baldissera E; Ravelli A; Salvarani C; Dagna L
Clin Exp Rheumatol; 2021; 39 Suppl 129(2):129-134. PubMed ID: 33666154
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the management of Takayasu arteritis.
Misra DP; Wakhlu A; Agarwal V; Danda D
Int J Rheum Dis; 2019 Jan; 22 Suppl 1():60-68. PubMed ID: 30698358
[TBL] [Abstract][Full Text] [Related]
19. Biological treatments in giant cell arteritis & Takayasu arteritis.
Samson M; Espígol-Frigolé G; Terrades-García N; Prieto-González S; Corbera-Bellalta M; Alba-Rovira R; Hernández-Rodríguez J; Audia S; Bonnotte B; Cid MC
Eur J Intern Med; 2018 Apr; 50():12-19. PubMed ID: 29146018
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab treatment effectively improves coronary artery involvement in patients with Takayasu arteritis.
Pan L; Du J; Liu J; Liao H; Liu X; Guo X; Liang J; Han H; Yang L; Zhou Y
Clin Rheumatol; 2020 Aug; 39(8):2369-2378. PubMed ID: 32144625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
